title: [Qiyusanlong decoction inhibits the level of PD-1/PD-L1 in mice bearing Lewis lung carcinoma].
abstract: Objective To investigate the anti-tumor effect of Qiyusanlong decoction (QYSL) in the mice with Lewis lung cancer (LLC) and its effect on the expression of programmed death 1 and programmed death ligand 1 (PD-1/PD-L1). Methods The model of lung cancer subcutaneous allograft was established using LLC cells. The model mice were randomly divided into six groups: a model group, a chemotherapy group, three QYSL groups of high, middle and low doses, and a combined group, each group containing 8 mice. On the 11th day, the low-, middle- and high-dose QYSL groups were respectively given intragastric administration of 20.12, 40.24, 80.48 g/(kg.d) QYSL; the chemotherapy group were intraperitoneally injected with 0.4 mL cisplatin; the combined group were administrated with cisplatin and high-dose QYSL; the model group were administrated with the same amount of normal saline, once a day for 10 days. Tumor volume was examined and tumor growth curve was drawn. Tumors were weighed and tumor inhibition rates were calculated. The expressions of PD-1, PD-L1 mRNA and protein in spleens and tumor tissues of mice were detected by real-time quantitative PCR and Western blotting, respectively. Results Compared with the model group, the high-dose QYSL group could inhibit tumor growth with tumor inhibition rate being 23.86%; the tumor inhibition rate between the combined group and the chemotherapy group was equal. The high-dose QYSL could significantly decrease the expression of PD-1 mRNA and protein in spleen and inhibited the expression of PD-L1 mRNA and protein in tumor. The levels of PD-1 and PD-L1 protein in the combined group were obviously lower than those in the chemotherapy group, but the interaction effect of the other indicators had no statistical significance. Conclusion QYSL can moderately inhibit the growth of the transplanted tumor by decreasing PD-1/PD-L1 level.
authors.affiliation: Hubei University of Chinese Medicine, Wuhan 430065; Institute of Chinese Medicine for Respiratory Diseases, Anhui Provincial Academy of Chinese Medical Sciences, Hefei 230038, China.
authors.forename: Xingxing
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Anhui University of Chinese Medicine, Hefei 230038; Institute of Chinese Medicine for Respiratory Diseases, Anhui Provincial Academy of Chinese Medical Sciences, Hefei 230038, China.
authors.forename: Jiabing
authors.initials: J
authors.lastname: Tong
authors.affiliation: Anhui University of Chinese Medicine, Hefei 230038; Institute of Chinese Medicine for Respiratory Diseases, Anhui Provincial Academy of Chinese Medical Sciences, Hefei 230038, China. *Corresponding author, E-mail: li6609@126.com.
authors.forename: Zegeng
authors.initials: Z
authors.lastname: Li
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D060890:B7-H1 Antigen / Q000235:genetics* / Q000378:metabolism; D015153:Blotting, Western; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D008297:Male; D008810:Mice, Inbred C57BL; D008517:Phytotherapy; D061026:Programmed Cell Death 1 Receptor / Q000235:genetics* / Q000378:metabolism; D011897:Random Allocation; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D047368:Tumor Burden / Q000187:drug effects / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; D004365:Drugs, Chinese Herbal; C491383:Pdcd1 protein, mouse; D061026:Programmed Cell Death 1 Receptor; D002945:Cisplatin